Biomarker Assays for Elevated Prostate-Specific Antigen Risk Analysis

Prostate cancer ranks among the most frequently detected malignancies in males, accounting for approximately 1.4 million new cases worldwide each year. This disease represents the most commonly diagnosed cancer and the second leading cause of cancer-related mortality in men, with an estimated 2.4 million cases projected for 2040, according to the National Cancer Institute (NCI). Approximately 1 in 8 men develops prostate cancer over a lifetime. Despite this high incidence, the typically indolent disease course contributes to a mortality rate of only 1 in 41 diagnosed men. One of the most effective approaches for screening, diagnosis, staging, assessment of therapeutic response, and prognostication in prostate cancer involves the use of serum or urine biomarkers for risk assessment. The NCI defines a biomarker as a biological molecule identified in blood, urine, other body fluids, or tissues that signals an abnormal process, condition, or disease. Appropriate application of biomarkers allows healthcare professionals to individualize diagnostic strategies while minimizing unnecessary diagnostic interventions and reducing the risk of overtreatment. The Early Detection Research Network represents an NCI-led initiative focused on identifying, developing, and validating novel biomarkers and emerging technologies to improve the accuracy and timeliness of cancer diagnosis. These biomarkers may include proteins, DNA, messenger RNA (mRNA), metabolites, prostate cancer cells or their derivatives, exosomes, or measurements of cellular processes, eg, proliferation or apoptosis. Several commercial risk-stratification biomarkers now support clinical evaluation of patients with persistently elevated prostate-specific antigen (PSA) levels and suspected prostate cancer. Beyond guiding clinical decision-making in low- or intermediate-risk patients with equivocal PSA values, surrogate biomarkers may be useful for assessing an individual patient’s response to a specific drug, procedure, or therapeutic intervention. Through this role, a biomarker can monitor treatment effectiveness for a defined disease or condition. Validated surrogate risk-stratification biomarkers frequently spare patients from prolonged clinical trials, unnecessary biopsies, costly imaging studies, or other invasive tissue-based diagnostic procedures.[2] An ideal biomarker demonstrates high sensitivity and specificity, straightforward use and interpretation, cost-effectiveness, broad availability, reproducibility, and reliable quantification from an easily obtainable specimen. Additional essential characteristics include a negative predictive value of at least 90%, approval by the Food and Drug Administration (FDA), compliance with Clinical Laboratory Improvement Amendments (CLIA) standards, and endorsement by the National Comprehensive Cancer Network (NCCN). Prostatic risk-stratification biomarkers serve primarily lower-risk and carefully selected borderline patients with mildly elevated PSA concentrations, generally ranging from 4 to 10 ng/mL, in whom unfavorable results often lead to avoidance of immediate additional testing, prostate imaging, biopsies, or other diagnostic procedures.[2] This activity examines the current landscape of available risk-stratification biomarkers as well as those under active investigation.